MckownLeopold151

Until recently, mothers have experienced to count on adult over-the-counter anti-fungal creams to treat their children' circumstances of diaper rash complicated by yeast infections. For the first time, a prescription product-Vusion™ (0.25] miconazole nitrate, 15] zinc oxide and 81.35] white petrolatum) Ointment-is available and is indicated and specifically developed for the treatment of this condition, called diaper dermatitis intricate by candidiasis (DDCC), in infants 4 weeks and older. Proof of DDCC is dependent upon microscopic evaluation for presence of pseudohyphae or budding yeast. DDCC is a highly prevalent rash in infants that will cause great discomfort and stress. Usually, DDCC infections are characterized by a rash of vivid red areas with irregular, raised edges and white scales on top. The main patches are often surrounded by smaller patches and painful lesions or blisters. Infants usually get DDCC when their diapers chafe and break the surface of the skin, making it easier for bacteria such as yeast to invade the skin. Other risk facets for DDCC include skin health, prolonged diaper allergy, diarrhea and the new use of broad-spectrum antibiotics. To research more, please check out] myrashguards.com/longsleeverashguards. The problem can happen anytime of year, but DDCC is usually induced inside the winter time when the utilization of antibiotics generally prescribed for illnesses such as ear infections are at its peak. Treatment selections have included the use of combination products and antifungal products, ste-roids that are not specifically approved for the cure of DDCC or for use on children. Visiting the best maybe provides tips you can give to your mom. 'With Vusion™ Ointment now approved for the U.S. Dig up more about my rash guards by visiting our thought-provoking portfolio. Industry, pediatricians and dermatologists could prescribe a treatment especially intended for the condition that it had been developed for and that is well tolerated for use on infants,' said Dr. Mary Spraker, a pediatric dermatologist and associate professor in Emory University's Department of Dermatology, who helped in the style of a Phase 3 clinical trial of the product. 'Doctors are no more reliant on suggesting antifungal agents designed for adults which have not been tried on children with DDCC.' Vusion™ Ointment was developed by Barrier Therapeutics, a Princeton, N.J.-based pharmaceutical company focused on the discovery, devel-opment and commercialization of goods in the field of dermatology..